David Foehr Sells 4,560 Shares of CeriBell (NASDAQ:CBLL) Stock

Key Points

• VP David Foehr sold 4,560 shares of CeriBell on March 3 at an average price of $17.80 for $81,168, leaving him with 17,550 shares — a roughly 20.62% reduction in his stake.
• Foehr has been a consistent seller this year, disposing of a total of 17,022 shares across five trades since January 5 (including two 5,556-share sales on Jan. 5 and Feb. 3 and smaller sales in February).
• For context, CeriBell trades around $17.79 with a market cap of about $669.6M, reported a quarterly EPS of ($0.36) that beat estimates and revenue of $24.78M, and carries an analyst consensus rating of “Moderate Buy” with a $24.67 price target.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 4,560 shares of the company's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.80, for a total value of $81,168.00. Following the transaction, the vice president directly owned 17,550 shares in the company, valued at approximately $312,390. This represents a 20.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The shares were sold at an average price of $19.98, for a total value of $15,604.38.
• On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $11,260.51.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.

CeriBell Trading Up 0.1%

CeriBell stock traded up $0.02 during trading hours on Thursday, reaching $17.79. 165,540 shares of the company's stock traded hands, compared to its average volume of 345,835. The firm has a market capitalization of $669.63 million, a price-to-earnings ratio of -12.10 and a beta of 1.12. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. CeriBell, Inc. has a fifty-two week low of $10.01 and a fifty-two week high of $24.33. The firm's 50 day moving average is $20.91 and its 200-day moving average is $16.41.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The business had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CBLL. TD Cowen reiterated a "buy" rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. cut their price target on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. Finally, BTIG Research restated a "buy" rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $24.67.

Hedge Funds Weigh In On CeriBell

Several institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 8,735.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company's stock worth $60,000 after purchasing an additional 2,708 shares in the last quarter. Invesco Ltd. increased its position in shares of CeriBell by 15.5% during the fourth quarter. Invesco Ltd. now owns 12,037 shares of the company's stock worth $264,000 after acquiring an additional 1,618 shares in the last quarter. Creek Drive Management Group LLC acquired a new stake in shares of CeriBell during the fourth quarter worth $4,253,000. nVerses Capital LLC bought a new stake in CeriBell in the 4th quarter valued at $282,000. Finally, Tudor Investment Corp ET AL acquired a new position in CeriBell in the 4th quarter worth $548,000.

CeriBell Company Profile

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.